Vertex Pharmaceuticals Inc VRTX
We take great care to ensure that the data presented and summarized in this overview for VERTEX PHARMACEUTICALS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VRTX
View all-
Capital World Investors Los Angeles, CA25.6MShares$11.4 Billion1.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA22.7MShares$10.1 Billion0.19% of portfolio
-
Black Rock Inc. New York, NY22MShares$9.78 Billion0.22% of portfolio
-
State Street Corp Boston, MA12MShares$5.35 Billion0.23% of portfolio
-
Alliancebernstein L.P. New York, NY7.1MShares$3.16 Billion1.08% of portfolio
-
Jpmorgan Chase & CO New York, NY6.02MShares$2.68 Billion0.23% of portfolio
-
Geode Capital Management, LLC Boston, MA5.81MShares$2.59 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA5.74MShares$2.56 Billion0.56% of portfolio
-
Jennison Associates LLC4.78MShares$2.13 Billion1.34% of portfolio
-
Wellington Management Group LLP Boston, MA4.56MShares$2.03 Billion0.35% of portfolio
Latest Institutional Activity in VRTX
Top Purchases
Top Sells
About VRTX
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Insider Transactions at VRTX
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 15
2024
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
69
-0.14%
|
$29,670
$430.93 P/Share
|
May 15
2024
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Open market or private sale
|
Direct |
32
-0.06%
|
$13,760
$430.93 P/Share
|
May 15
2024
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
54
-0.21%
|
$23,220
$430.93 P/Share
|
May 15
2024
|
Jennifer Schneider Director |
BUY
Grant, award, or other acquisition
|
Direct |
922
+50.0%
|
-
|
May 14
2024
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
BUY
Grant, award, or other acquisition
|
Direct |
14,112
+31.93%
|
-
|
May 02
2024
|
Sangeeta N. Bhatia Director |
SELL
Open market or private sale
|
Direct |
467
-9.53%
|
$187,734
$402.95 P/Share
|
May 01
2024
|
Suketu Upadhyay Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,168
-31.34%
|
-
|
May 01
2024
|
Suketu Upadhyay Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,001
+21.17%
|
-
|
May 01
2024
|
Nancy Thornberry Director |
BUY
Grant, award, or other acquisition
|
Direct |
501
+23.43%
|
-
|
May 01
2024
|
Diana Mckenzie Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
1,168
-32.41%
|
-
|
May 01
2024
|
Diana Mckenzie Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,001
+21.74%
|
-
|
May 01
2024
|
Sangeeta N. Bhatia Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,001
+16.96%
|
-
|
May 01
2024
|
Lloyd Carney Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,001
+13.67%
|
-
|
Apr 02
2024
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
240
-3.1%
|
$100,560
$419.0 P/Share
|
Apr 01
2024
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
225
-2.82%
|
$94,050
$418.1 P/Share
|
Feb 26
2024
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Open market or private sale
|
Direct |
3,004
-5.15%
|
$1,276,700
$425.7 P/Share
|
Feb 26
2024
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
354
-0.63%
|
$150,450
$425.7 P/Share
|
Feb 26
2024
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
SELL
Open market or private sale
|
Direct |
883
-5.24%
|
$375,275
$425.7 P/Share
|
Feb 26
2024
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
5,034
-9.2%
|
$2,139,450
$425.7 P/Share
|
Feb 26
2024
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
883
-9.98%
|
$375,275
$425.7 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 281K shares |
---|---|
Exercise of conversion of derivative security | 66.8K shares |
Sale (or disposition) back to the issuer | 2.34K shares |
---|---|
Open market or private sale | 246K shares |
Payment of exercise price or tax liability | 134K shares |